Rapport Therapeutics Announces Pricing of Initial Public Offering
06 juin 2024 18h54 HE
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
02 mai 2024 08h01 HE
|
STALICLA
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the...
New YPrime Report Highlights eCOA's Impact on CNS Trials
01 mai 2024 08h00 HE
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
30 avr. 2024 08h00 HE
|
Alumis Inc
Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.
FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
11 avr. 2024 07h00 HE
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experienceDr. Beher...
Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
01 mars 2024 08h00 HE
|
Alumis Inc
– A-005 is a potential first-in-class, brain penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – – Data support planned Phase 1 clinical trial on track to...
Stem Cell Assays Market Size & Share to Surpass USD 8.5 billion by 2033 | Analysis by Transparency Market Research
18 janv. 2024 09h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global stem cell assays market is estimated to flourish at a CAGR of 16.5% from 2023 to...
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
02 nov. 2023 08h00 HE
|
Ractigen Therapeutics
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders
19 oct. 2023 11h45 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the “Special...
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
16 oct. 2023 08h11 HE
|
Silo Pharma, Inc.
Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...